A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals.

@article{Sugrue1990ACO,
  title={A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals.},
  author={Michael F. Sugrue and Pierre J. Mallorga and Harvey Schwam and John J. Baldwin and Gerald S. Ponticello},
  journal={Current eye research},
  year={1990},
  volume={9 6},
  pages={
          607-15
        }
}
L-671,152 is a water-soluble, carbonic anhydrase inhibitor structurally similar to MK-927, a carbonic anhydrase inhibitor that, on topical administration, lowers the intraocular pressure (IOP) of experimental animals and humans. L-671,152 was more potent than MK-927 at inhibiting purified, human erythrocyte carbonic anhydrase II in vitro, as reflected in their respective IC50 values of 0.16 nM and 1.19 nM. Both compounds were compared for topical, ocular hypotensive activity in pigmented… 
MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys.
TLDR
The results suggest that MK-507 reduces intraocular pressure by decreasing aqueous humor production as well as water-soluble inhibitor of human carbonic anhydrase II in vitro.
The effect of cyclooxygenase inhibition on the ocular hypotensive action of topical carbonic anhydrase inhibitors in rabbits.
TLDR
These studies indicate that the IOP lowering actions of the three CAIs, unlike that of epinephrine, in rabbits are not mediated by endogenous prostaglandins and/or other prostanoids.
The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor.
  • M. F. Sugrue
  • Chemistry, Medicine
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • 1996
TLDR
The topical administration of 0.5%, 1% and 2% solutions of dorzolamide maximally lowered the intraocular pressure (IOP) of glaucomatous monkeys by 22, 30% and 37%, respectively, and good ocular hypotensive activity was also observed in ocular normotensive and hypertensive rabbits.
Two topical carbonic anhydrase inhibitors sezolamide and dorzolamide in Gelrite vehicle: A multiple-dose efficacy study
TLDR
Duration of action of both compounds was, at most, slightly prolonged by the use of Gelrite vehicle when compared with former studies on sezolamide and dorzolam, although the decrease in IOP for sezoramide tended to be slightly greater than that for dorZolamide.
Topically active carbonic anhydrase inhibitors for glaucoma.
TLDR
A 35-year search for an active topically administered carbonic anhydrase inhibitor is reaching fruition thanks largely to the efforts of Thomas Maren of the University of Florida.
Carbonic Anhydrase Inhibitors in the Treatment of Glaucoma. Review. Part I
TLDR
The mechanisms of action of the drugs aimed at carbonic anhydrase blocking are considered, and the results of various studies of 2 % dorozolamide and 1 % brinzolamide, as well as their fixed combinations, are analyzed.
Six week safety study of 2% MK-927 administered twice daily to ocular hypertensive volunteers.
TLDR
In this longest chronic administration study to date, MK-927 did not cause adverse ocular or systemic side effects and hematologic studies were not substantially altered throughout the study.
Ocular hypotensive effects of a Rho-associated protein kinase inhibitor in rabbits
TLDR
Ripasudil has stronger IOP-lowering effects than timolol, pilocarpine or dorzolamide hypotensive agents in the authors' rabbit model.
...
...

References

SHOWING 1-10 OF 23 REFERENCES
L‐662,583 is a topically effective ocular hypotensive carbonic anhydrase inhibitor in experimental animals
TLDR
The ocular normotensive, albino rabbit was much less susceptible than the ocular hypertensive rabbit to the intraocular pressure lowering effect of topically applied L‐662,583, with a 2% solution maximally decreasing intraocular Pressure by 2.3 mmHg.
Local tolerance and activity of MK-927, a novel topical carbonic anhydrase inhibitor.
TLDR
Local tolerance of 2% MK-927 was acceptable and supports further clinical trials in patients and significant intraocular pressure-lowering activity was noted when comparing IOP four hours after first dose with that 20 hours predose in the treated eye of subjects receiving MK- 927.
On the pharmacology of L-645,151: a topically effective ocular hypotensive carbonic anhydrase inhibitor.
TLDR
Preclinical studies reveal that L-645,151 is the most potent, topically effective ocular hypotensive carbonic anhydrase inhibitor described to date.
The effect of MK-927, a topical carbonic anhydrase inhibitor, on IOP in glaucomatous monkeys.
TLDR
Topical administration of MK-927 reduces intraocular pressure (IOP) in rabbits and appears to have great clinical potential after initial single-dose trials of various concentrations.
MK-927: a topically effective carbonic anhydrase inhibitor in patients.
TLDR
The effects on intraocular pressure of the novel topical carbonic anhydrase inhibitor MK-927 were investigated for the first time in patients in a two-center, double-masked, randomized, placebo-controlled, two-period crossover study in patients with bilateral primary open angle glaucoma or ocular hypertension.
MK-927: a topical carbonic anhydrase inhibitor. Dose response and duration of action.
TLDR
The dose response to a single topical administration of the carbonic anhydrase inhibitor MK-927 was investigated in 24 patients with primary open angle glaucoma or ocular hypertension and appeared to lower intraocular pressure in a dose-dependent fashion.
Ocular distribution studies of the topical carbonic anhydrase inhibitors L-643,799 and L-650,719 and related alkyl prodrugs.
TLDR
The ocular distribution of the carbonic anhydrase inhibitors 6-hydroxybenzothiazide-2-sulphonamide and L-650,719 has been investigated in albino rabbits after conjunctival administration of these compounds or related alkyl prodrugs.
Carbonic anhydrase inhibitor side effects. Serum chemical analysis.
TLDR
Patients with chronic glaucoma complained of a symptom-complex of malaise, fatigue, weight loss, depression, anorexia, and loss of libido, which has found most commonly to threaten continuation of therapy.
Carbonic anhydrase: General perspective and advances in glaucoma research
The chemistry and physiology of carbonic anhydrase are reviewed in relation to pharmacological progress in the development of sulfonamide inhibitors. The major organ systems are briefly dicussed.
...
...